Syncona Leads $80 Million Round for Gene Therapy Firm Autolus – New York Times
|
Syncona Leads $80 Million Round for Gene Therapy Firm Autolus
New York Times LONDON — Syncona has led a $80 million investment in Autolus, a company developing gene therapies to treat cancer, the healthcare investment group said on Tuesday. Gene-modifying immunotherapy is a new type of cancer treatment that harnesses the … |
